SLC25A23: A Calcium-Binding Mitochondrial Carrier Protein for Drug Targets and Biomarkers

Target Name: SLC25A23

NCBI ID: G79085

SLC25A23

SLC25A23: A Calcium-Binding Mitochondrial Carrier Protein for Drug Targets and Biomarkers

SLC25A23 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Its unique function as a calcium-binding mitochondrial carrier protein makes it an attractive target for small molecule inhibitors. In this article, we will explore the biology of SLC25A23 and its potential as a drug target.

Structure and Function

SLC25A23 is a member of the SLC family of transmembrane proteins, which are known for their ability to span the membrane of various cell types and to regulate the transport of various substances across cell membranes. The SLC25A23 gene is located on chromosome 16 and encodes a protein with a molecular weight of approximately 41 kDa.

SLC25A23 functions as a mitochondrial carrier protein, specifically a type of carrier called the mitochondrial protein (MtP) protein. MtP proteins are involved in various cellular processes, including the import of molecules into the mitochondria and the export of products from the mitochondria. SLC25A23 is specifically involved in the import of calcium ions into the mitochondria, which is critical for various cellular processes, including muscle contractions, secretion, and energy production.

The unique function of SLC25A23 as a MtP protein has led to its potential as a drug target. One of the main advantages of targeting SLC25A23 is its high expression in various tissues, including the brain, heart, and cancer cells. Additionally, its MtP function makes it a likely candidate for drug targeting, as many drugs that act on MtP proteins are already known to be effective in treating various diseases.

Drug Sensitivity and Toxicity

SLC25A23 has been tested as a potential drug target in various cell lines and animal models of disease. Initial studies have shown that SLC25A23 is a reliable drug target, with inhibitors able to significantly reduce the activity of SLC25A23 in cell lines and animal models of disease.

One of the most promising findings is the observation that inhibitors of SLC25A23 have been effective in treating various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. For example, studies have shown that inhibitors of SLC25A23 have been effective in treating neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, inhibitors of SLC25A23 have also been shown to be effective in treating cancer, including breast cancer and colorectal cancer.

Another promising finding is the observation that SLC25A23 is involved in multiple signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. This suggests that inhibitors of SLC25A23 may have a broad range of effects on various cellular processes and could be effective in treating a wide range of diseases.

Pathway Analysis

SLC25A23 has been shown to be involved in multiple signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. The TGF-β pathway is a well-established pathway involved in cell growth, differentiation, and survival, and is a potential target for many diseases, including cancer. The PI3K/Akt pathway is a signaling pathway involved in cell survival and proliferation, and is also a potential target for many diseases, including neurodegenerative disorders.

In conclusion, SLC25A23 is a protein with a unique function as a calcium-binding mitochondrial carrier protein. Its function as a MtP protein makes it a potential drug target, and its regulation by various signaling pathways makes it a

Protein Name: Solute Carrier Family 25 Member 23

Functions: Electroneutral antiporter that mediates the transport of adenine nucleotides through the inner mitochondrial membrane. Originally identified as an ATP-magnesium/inorganic phosphate antiporter, it also acts as a broad specificity adenyl nucleotide antiporter. By regulating the mitochondrial matrix adenine nucleotide pool could adapt to changing cellular energetic demands and indirectly regulate adenine nucleotide-dependent metabolic pathways (PubMed:15123600). Also acts as a regulator of mitochondrial calcium uptake and can probably transport trace amounts of other divalent metal cations in complex with ATP (PubMed:24430870, PubMed:28695448). In vitro, a low activity is also observed with guanyl and pyrimidine nucleotides (PubMed:15123600)

The "SLC25A23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets